Literature DB >> 15527848

Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site.

Wenlong Han1, Megan Wind-Rotolo, Richard L Kirkman, Casey D Morrow.   

Abstract

The initiation of HIV-1 reverse transcription occurs at an 18-nucleotide sequence in the viral genome designated as the primer binding site (PBS), which is complementary to the 3' terminal nucleotides of tRNA(Lys,3). Since the PBS is highly conserved among all infectious HIV-1, it represents an attractive target for the development of new therapeutics to inhibit viral replication. In this study, we have evaluated three approaches using small interfering RNA (siRNAs) targeted to the PBS for the capacity to inhibit HIV-1 replication. In the first, transfection of a 21-nucleotide siRNA complementary to the PBS into cells inhibited production of HIV-1 following infection. Control siRNAs of the same length complementary to HIV-1 gag mRNA or to gfp mRNA decreased the production of virus or had no effect on virus replication, respectively. Analysis of the PBS of integrated proviruses derived from viruses that ultimately grew in cultures transfected with siRNA all contained wild-type PBS sequence, demonstrating that HIV-1 did not mutate to escape inhibition by siRNA. In the second approach, hairpin siRNA targeted to the wild-type PBS were expressed using an adeno-associated virus (AAV) vector. HIV-1 replication was inhibited in cells infected with AAV encoding the siRNA to the wild-type PBS, but not in cells infected with AAV encoding an siRNA of the same length targeted to an irrelevant PBS. Finally, studies from this laboratory have shown that alteration of the PBS to be complementary to tRNAHis results in the production of infectious virus that rapidly reverts to utilize tRNALys,3 following in vitro culture. A proviral genome containing a PBS complementary to tRNAHis that encodes an siRNA molecule complementary to the wild-type PBS under control of a U6 promoter within the nef gene was as infectious as the parent HIV-1 genome containing no insert in nef. The virus with the PBS only complementary to tRNAHis reverted to use tRNALys,3, coincident with rapid virus growth, while the virus encoding siRNA grew slower than the virus without siRNA and maintained the PBS complementary to tRNAHis longer in culture. At later times of infection, viruses with the PBS complementary to tRNAHis and the siRNA exhibited a rapid increase in p24 antigen in the culture. Analysis of the PBS revealed that it was now complementary to tRNALys,3. Analysis of the gene encoding the siRNA revealed that the reversion of the PBS coincided with the deletion of the gene encoding siRNA. The results of these studies show that siRNA targeted to the PBS of HIV-1 can inhibit virus replication, supporting the concept that HIV-1 has evolved a strong preference to select tRNALys,3 for high-level replication and establishing the PBS and primer selection as a potential target for new therapeutics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15527848     DOI: 10.1016/j.virol.2004.09.027

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome.

Authors:  Snehlata Tripathi; Binay Chaubey; Beverly E Barton; Virendra N Pandey
Journal:  Virology       Date:  2007-02-21       Impact factor: 3.616

2.  Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.

Authors:  Touraj Farazmandfar; Mohammad Reza Haghshenas; Majid Shahbazi
Journal:  Hum Gene Ther       Date:  2015-08-06       Impact factor: 5.695

3.  Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site.

Authors:  Scott R Eberhardy; Joao Goncalves; Sofia Coelho; David J Segal; Ben Berkhout; Carlos F Barbas
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 4.  AAV hybrid serotypes: improved vectors for gene delivery.

Authors:  Vivian W Choi; Douglas M McCarty; R Jude Samulski
Journal:  Curr Gene Ther       Date:  2005-06       Impact factor: 4.391

5.  Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.

Authors:  Ke-Qin Xin; Hiroaki Mizukami; Masashi Urabe; Yoshihiko Toda; Kaori Shinoda; Atsushi Yoshida; Kenji Oomura; Yoshitsugu Kojima; Motohide Ichino; Dennis Klinman; Keiya Ozawa; Kenji Okuda
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

Review 6.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

Review 7.  Lentiviral delivery of short hairpin RNAs.

Authors:  N Manjunath; Haoquan Wu; Sandesh Subramanya; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2009-03-31       Impact factor: 15.470

8.  Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid.

Authors:  Man Lung Yeung; Yamina Bennasser; Koichi Watashi; Shu-Yun Le; Laurent Houzet; Kuan-Teh Jeang
Journal:  Nucleic Acids Res       Date:  2009-09-03       Impact factor: 16.971

9.  A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs.

Authors:  Olivier ter Brake; Ben Berkhout
Journal:  J RNAi Gene Silencing       Date:  2005-10-14

10.  Transcription-dependent gene looping of the HIV-1 provirus is dictated by recognition of pre-mRNA processing signals.

Authors:  Kelly J Perkins; Marina Lusic; Ivonne Mitar; Mauro Giacca; Nick J Proudfoot
Journal:  Mol Cell       Date:  2008-01-18       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.